The Role Clay Siegall Plays In the Field Of Cancer Research

Many companies are making significant discoveries in the field of cancer research. One of the enterprises that has been an interesting factor in this area is the Seattle Genetics. The CEO of the firm is Clay Siegall. The company focuses on some innovations as it makes some significant changes in the therapy for cancer. The stock price of the company has increased by three times in just five years. As the CEO of the company, Clay Siegall has a passion for improving the lives of the patients of cancer. He has had this passion since he began his career in studies of biomedical.

Clay Siegall has been serving as the CEO of the Seattle Genetics Firm since the year 2002. He has been contributing his services to the company for about two decades of history. He was a co-founder of the company when it began in 1998. Since that time, he has been working to make some significant advancements in cancer research. The company has come up with some great therapies for the cancer patients.

Under the leadership of Clay Siegall, the Seattle Genetics company has been able to enter into a couple of strategic licenses for the technology of ADC. Some of them include; GlaxoSmithKline, Pfizer, and Genentech. This has helped in the generation of more than 300 million dollars. There are more than 20 ADCs in the clinical development across all the collaborator and internal programs. Dr. Siegall has also helped in the in the activities that raise Seattle Genetics. They have been able to secure more than 675 million dollars from both private and public financings.

Clay Siegall is also a writer. He now has about 70 publications. He has a total of about 15 patents. Before he was a co-founder of the Seattle Genetics Company, he was able to provide his services at the National Cancer Institute from the year 1991 to 1997. He was also able to work with the National Institute of health from 1988 to 1991. Apart from this, he is also a board member of some institutes. Some of them include the Mirna Therapeutics, Ultralgenyx pharmaceutical, and the Washington Roundtable.